Overview

A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Status:
Completed

Trial end date:
2018-10-25

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate whether treatment with ibrutinib as a monotherapy results in a clinically significant improvement in progression free survival (PFS) as compared to treatment with ofatumumab in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Phase:

Phase 3

Details

Lead Sponsor:

Pharmacyclics LLC.

Collaborator:

Janssen Research & Development, LLC

Treatments:

Antibodies, Monoclonal
Ofatumumab